On Thursday, Tempur-Pedic International reported to SEC filings that the company made staggering income of $46.29 million which was ahead of analysts expectations. Net Sales for the final quarter of 2010 rose more than 20% up to $292.7 million dollars and now some investors are placing the company on its stocks to buy now list.
In beating the Wall Street analysts' expectations was in the form of price per share in regards to revenue and they predicted that it would be at or around $0.57 per share, however Tempur-Pedic beat expectations in this category as well with reporting $0.66 per share.
That is a significant increase from last year's price per share filing which was $0.38. The most notable statistic from this quarters Tempur-Pedic earnings filing report was that the company cut down on their debt roughly $29 million down to a total of $407 million and increased cash-on-hand to $53.6 million.
In accordance with solid revenues, the company did announce a new share purchase program that would allow for a float of an extra $200million in share equity.
PANACEA BIOTECH is looking strong on charts, if it sustains above 120 levels. We advise buying around 115-120 levels with strict stop loss of 110 for the targets 125 -130 levels. epicresearch.co
ReplyDelete